Ibogaine is not safe in the way an over-the-counter medicine is safe. It carries a genuine cardiac risk, it has been associated with deaths, and it should never be taken without medical screening and monitoring.
It is also true that in properly run medical programmes — with cardiac screening beforehand and continuous monitoring throughout — serious complications are rare. Dr. Bruno Rasmussen, for example, has carried out more than 2,000 supervised ibogaine treatments in Brazilian hospitals since 1994.
Both of those statements are true at once, and the distance between them is the entire subject of this article. Ibogaine’s safety is determined less by the molecule than by the protocol around it.
What the actual risk is
Ibogaine’s principal danger is cardiac, and it is specific rather than vague.
Ibogaine slows the heart rate (bradycardia) and prolongs the QT interval — a measure of how long the heart’s electrical system takes to reset between beats. A prolonged QT interval raises the risk of dangerous arrhythmia. In a healthy, screened patient in a monitored setting, this is a known and observable effect. In someone with an undiagnosed cardiac condition, an electrolyte imbalance, or stimulants still in their system, it is how ibogaine kills people.
This is why every element of a responsible protocol — the ECG, the blood tests, the waiting periods, the monitoring hours — exists to address one question: is this person’s heart in a state where this compound is safe to give?
Two further pharmacological facts matter clinically. Ibogaine increases the toxicity of opioids, so a patient must have as little opioid circulating as possible at the time of treatment. And it remains active in the body long after the acute experience ends, which makes what a patient takes in the days afterwards a genuine safety issue rather than a lifestyle question.
Why deaths have happened
Ibogaine-associated deaths are real and should not be minimised. But the pattern in them is consistent, and it is worth understanding precisely, because it is what separates the settings where people die from the settings where they don’t.
Fatalities have overwhelmingly occurred outside proper medical supervision — in hotel rooms, private homes and unregulated “retreats”, where no ECG was performed, no bloodwork was reviewed, and no one was equipped to respond to an arrhythmia. Where ibogaine is illegal, treatment moves underground, and underground is where the harm concentrates.
A second pattern concerns attribution. A proportion of deaths recorded as ibogaine-related involved other substances — an opioid taken after the session while ibogaine was still active in the body, or a contraindicated drug in combination. The death is reported against ibogaine; the mechanism was the interaction.
The clinical principle is blunt: preventing arrhythmia matters far more than treating it. Prevention happens before the patient is ever dosed.
How risk is actually managed
What follows is the protocol used in Dr. Rasmussen’s hospital-based programme in Brazil. It is a useful benchmark: not because every clinic must copy it exactly, but because it shows what genuine medical caution looks like in practice.
Screening — before anything else
Every candidate undergoes an ECG, blood tests and a full clinical review, alongside a psychological evaluation. The purpose is not to clear people through; it is to identify who should not be treated. In responsible programmes, a significant share of applicants are found unsuitable and are turned away.
That rejection rate is one of the most useful safety signals a prospective patient can ask about.
Substance-specific preparation
Preparation differs by drug, for concrete physiological reasons.
Cocaine and crack. Stopping stimulants lowers the heart rate; ibogaine lowers it further and prolongs the QT interval. Combine the two and the cardiac risk compounds. Patients are therefore asked to stop cocaine or crack for around four weeks before treatment — a demanding requirement that some find paradoxical, and the reason it is imposed anyway is that this is precisely where complications would otherwise occur.
Opioids. Because ibogaine makes opioids more toxic, patients on long-acting drugs such as methadone are first switched to a short-acting opioid. Treatment then begins once early withdrawal has appeared — the visible signs that little opioid remains in circulation.
Compliance is verified rather than assumed: patients are monitored at home with weekly toxicology tests, and a final test is carried out immediately before dosing.
During treatment
Treatment takes place in a hospital — in São Paulo state, this is a legal requirement, and the practical reason is straightforward: a hospital has the equipment and the team to respond immediately if something goes wrong, including intensive-care access.
Patients arrive on an empty stomach, which reduces the risk of vomiting the medication. Dosing is calculated by body weight. The patient remains in a private room under continuous monitoring, typically for 24 to 48 hours.
Discharge and afterwards
Discharge happens only when the patient is medically stable, and they must be accompanied when they leave. A day or two of rest is planned in.
The critical safety point in this period is one patients frequently underestimate: ibogaine remains active for days. Taking one’s previous dose of any substance after the session — a common relapse pattern, and precisely the scenario in which withdrawal and craving have disappeared — is genuinely dangerous, not merely a setback.
Who should not take ibogaine
Ibogaine is contraindicated, or requires resolution before treatment can be considered, in cases including:
- Cardiac conditions — existing arrhythmia, structural heart disease, a prolonged QT interval, or a relevant family history
- Psychiatric conditions such as psychosis or schizophrenia
- Liver impairment, since ibogaine is metabolised there
- Medication interactions — a number of common drugs, including some antidepressants and anything that affects the QT interval, must be reviewed and often adjusted well in advance
- Recent stimulant use, per the preparation window above
- Electrolyte imbalance, which is often correctable — and is one reason bloodwork is not a formality
This list is illustrative, not exhaustive, and no page on the internet can tell you which category you fall into. That determination requires a physician reviewing your actual test results and medication list.
What the published evidence shows
The safety data on ibogaine is limited, because its legal status has made large formal trials difficult to run. The most directly relevant published work comes from Brazil.
In a retrospective study co-authored by Dr. Rasmussen and published in the Journal of Psychopharmacology in 2014, 75 patients treated for alcohol, cannabis, cocaine and crack dependence were reviewed. The authors reported no serious adverse reactions and no fatalities, and concluded that physician-supervised ibogaine combined with psychotherapy could facilitate prolonged abstinence.
Two honest caveats. A retrospective review of one programme is weaker evidence than a randomised controlled trial — it describes what happened there, not what happens everywhere. And that cohort was non-opioid, so its safety findings should not simply be transferred to opioid patients, for whom the interaction risk is different and the preparation more demanding.
Ibogaine research and evidence →
Questions worth asking any clinic
If you take one practical thing from this page, take this list. Ask any provider you are considering:
- Do you require an ECG and blood tests before treatment, and who reviews them?
- Is a physician physically present throughout the session?
- What monitoring equipment is used, and for how many hours?
- What is your setting — hospital, licensed medical facility, or residential?
- What happens if a cardiac emergency occurs — what is on site, and how far is the nearest intensive care?
- What proportion of applicants do you turn down?
- How do you prepare opioid patients, and what do you require of stimulant users beforehand?
- What psychological support is included before and after?
For us, hesitation on questions one through five is disqualifying. A provider that cannot answer question six has probably never asked it of itself.
How to choose an ibogaine clinic →
Our position
We are not a clinic, and we will say it plainly: we do not work with providers that skip cardiac screening, and we regularly tell people that ibogaine is not appropriate for their case. If your medical history rules it out, the useful outcome of contacting us is finding that out from a physician’s review rather than discovering it in a hotel room.
Free and confidential. Our team reviews your request — including the medical screening questions — and replies within 24 hours.